Phase 2 data suggest new drug could unlock shorter TB treatment An international team of investigators today announced promising data from a trial of a novel antibiotic that could potentially shorten and simplify treatment for tuberculosis (TB) patients The interim data from the phase 2 trial, released yesterday at the Union World Conference on Lung Health in
New drug could be a breakthrough in treatment for killer TB . . . Sorfequiline, a new antibiotic, showed stronger action against the deadly bacteria than existing treatments, with a comparable safety profile, researchers from the TB Alliance told the Union Conference on Lung Health in Copenhagen on Wednesday
New TB Trial Data Shows Sorfequiline Could Dramatically . . . A major breakthrough in tuberculosis (TB) drug development is emerging New phase 2 clinical trial results presented by TB Alliance at the Union World Conference on Lung Health indicate that sorfequiline (TBA-876) — a next-generation diarylquinoline antibiotic — could significantly improve and shorten TB treatment when used in the investigational SPaL regimen (sorfequiline + pretomanid
New Antibiotic Sorfequiline Shows Stronger Activity Than . . . Early clinical trial results show that the new antibiotic sorfequiline, used in the SPaL regimen, demonstrated stronger activity than bedaquiline and could help shorten tuberculosis treatment for both drug-resistant and drug-sensitive TB
Sorbequiline, a new antibiotic likely to serve as a . . . - MSN US foreign aid cuts could trigger additional 22 lakh deaths in high-burden TB countries, reveals Study Sorbequiline, a new antibiotic likely to serve as a breakthrough in Tuberculosis treatment
New Antibiotic Could Be a Breakthrough in Treatment for . . . A new treatment for tuberculosis could boost cure rates and shorten the time needed to treat the disease by months, trial results suggest The Guardian: Globally, an estimated 10 7 million people fell ill with TB last year and 1 23 million died from it In its annual report on tuberculosis, launched